New HIV vaccine combo enters first human safety trial
NCT ID NCT06905275
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests two experimental HIV vaccines, UVAX-1107 and UVAX-1197, in 25 healthy adults without HIV. The goal is to check if the vaccines are safe and whether they trigger an immune response. Participants will receive injections and be followed for about a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UVAX-1107 and UVAX-1197 vaccines with 3M-052-AF + alum adjuvant
What this could lead to
If successful, this could point toward a safe and effective HIV vaccine that trains the immune system to fight the virus.
What could go wrong
This is a very early Phase 1 trial with only 25 people, so it is too soon to know if the vaccines will work. The study is also currently suspended, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS (#31788)
Birmingham, Alabama, 35222, United States
-
Columbia P&S CRS (#30329)
New York, New York, 10032, United States
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
-
Vanderbilt Vaccine (VV) CRS (#30352)
Nashville, Tennessee, 37232, United States